

## PRESS RELEASE

### Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial

Maastricht, Netherlands, 18<sup>th</sup> June, 2024 - Pie Medical Imaging, a global leader in cardiac imaging, announced the **completion of enrollment in FASTIII**, a **multi-center randomized clinical trial, which investigates the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures. vFFR can assess whether a coronary artery narrowing is functionally significant and may require revascularization.**

**FASTIII is the largest non-inferiority trial running** (having enrolled 2228 patients), in which an angiographically derived **vFFR guided strategy is compared to a FFR guided strategy to guide coronary revascularization**. The primary endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization at 1-year post randomization.

Following the tremendous efforts of the principal investigator, **Dr Joost Daemen** (cardiologist at Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), over 35 participating centers and ECRI (sponsor of the trial), the patient enrollment has concluded.

***“The FASTIII trial is aimed to establish the role of vFFR to coronary revascularization in patients with intermediate coronary artery lesions. An important milestone was reached Friday, May 31<sup>st</sup>, 2024, when the last patient was enrolled”, said Joost Daemen Principal Investigator of the trial. “The next phase will consist of close follow-up of all patients who generously agreed to participate in the important trial. We hope to present our findings by the end of 2025”.***

Additionally, *“PMI is committed to providing clinicians and patients with long-term coronary data to inform their treatment decisions, “ said René Guillaume, Managing Director at Pie Medical Imaging. **“Our prior studies have shown diagnostic accuracy and reproducibility of vFFR calculation”.** FASTIII will establish its role in routine clinical practice.*

**The trial is funded by research grants from Pie Medical Imaging (Maastricht, The Netherlands) and Siemens Healthineers (Erlangen, Germany). The study is sponsored by ECRI (European Cardiovascular Research Institute, Rotterdam-the Netherlands). Cardialysis (Rotterdam, The Netherlands) is responsible for trial services including trial management and Core Laboratory activities.**

#### About Pie Medical Imaging

**Pie Medical Imaging BV** is a world leader in analysis and visualization of cardiovascular images. In Maastricht (The Netherlands), it hosts the global sales for the CAAS and 3mensio product lines. PMI and 3mensio Medical Imaging **part of the Esaote Group**, leader in the biomedical equipment sector. More information about PMI is available at [www.piemedicalimaging.com](http://www.piemedicalimaging.com)

#### Contacts:

Tristan Slots - PMI T: 043 328 13 28 [pmi@pie.nl](mailto:pmi@pie.nl), [Tristan.Slots@pie.nl](mailto:Tristan.Slots@pie.nl)

#### Esaote Group:

Mariangela Dellepiane, Head of Communications and External Relations, Esaote Group, [mariangela.dellepiane@esaote.com](mailto:mariangela.dellepiane@esaote.com) | mob.: + 393351289783



Fede Gardella, Press Office |tel.: +393358308666, [esaotepress@esaote.com](mailto:esaotepress@esaote.com)